Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-009: Adjuvant Pembrolizumab With or Without V940 in NSCLC
NCT06623422Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- May 2033
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + Intismeran autogene with Pembrolizumab + Placebo (2 arms). Primary endpoint: Disease-Free Survival at 97 months. Started Oct 2024; status: recruiting.
02
Drugs
intismeran autogene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06623422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623422.